Tocotrienol-Rich Fraction Modulates Amyloid Pathology and Improves Cognitive Function in AβPP/PS1 Mice

Journal of Alzheimer's Disease

Volumn 55, Issue 2, 2017, Pages 597-612

  Ibrahim, Nor Faeizah ^a,b   Yanagisawa, Daijiro ^a   Durani, Lina Wati ^a,b   Hamezah, Hamizah Shahirah ^a,b   Damanhuri, Hanafi Ahmad ^b   Wan Ngah, Wan Zurinah ^b   Tsuji, Mayumi ^c   Kiuchi, Yuji ^c   Ono, Kenjiro ^c   Tooyama, Ikuo ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; amyloid ; A PP PS1 mice; tocotrienol rich fraction; Vitamin E

Indexed keywords

ALPHA TOCOTRIENOL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; PEPTIDE FRAGMENT; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CELL VIABILITY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FLUORESCENCE; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PATHOGENESIS; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; NEUROBLASTOMA; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIOXIDANTS; CELL LINE, TUMOR; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEUROBLASTOMA; PEPTIDE FRAGMENTS; PRESENILIN-1; TOCOTRIENOLS;

EID: 84999268236     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160685     Document Type: Article

References (57)

1. Selkoe DJ (1997) Alzheimer's disease-genotypes, phenotypes, and treatments. Science 275, 630-631.
2. Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: Relations to -amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68, 209-245.
3. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
4. Blennow K, Leon MJd, Zetterberg H (2006) Alzheimer's Disease. Lancet 368, 387-403.
5. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710-713.
6. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) APP locus duplication causes autosomal dominant earlyonset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26.
7. Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer's disease: Cholesterol and beyond. Nat Rev Neurosci 12, 284-296.
8. Horvath G, Wessjohann L, Bigirimana J, Jansen M, Guisez Y, Caubergs R, HoremansN(2006) Differential distribution of tocopherols and tocotrienols in photosynthetic and nonphotosynthetic tissues. Phytochemistry 67, 1185-1195.
9. Sundram K, Sambanthamurthi R, Tan YA (2003) Palm fruit chemistry and nutrition. Asia Pac J Clin Nutr 12, 355-362.
10. Sen CK, Rink C, Khanna S (2010) Palm oil-derived natural vitamin E alpha-tocotrienol in brain health and disease. J Am Coll Nutr 29(3 Suppl), 314S-323S.
11. Chin SF, Ibahim J, Makpol S, Abdul Hamid NA, Abdul Latiff A, Zakaria Z, Mazlan M, Mohd Yusof YA, Abdul Karim A, Wan Ngah WZ (2011) Tocotrienol rich fraction supplementation improved lipid profile and oxidative status in healthy older adults:Arandomized controlled study. Nutr Metab (Lond) 8, 42.
12. Fukui K, Nakamura K, Shirai M, Hirano A, Takatsu H, Urano S (2015) Long-term vitamin E-deficient mice exhibit cognitive dysfunction via elevation of brain oxidation. J Nutr Sci Vitaminol (Tokyo) 61, 362-368.
13. Khor SC, MohdYusofYA,Wan Ngah WZ,Makpol S (2015) Tocotrienol-rich fraction prevents cellular aging by modulating cell proliferation signaling pathways. Clin Ter 166, e81-e90.
14. Zhang JS, Zhang SJ, Li Q, Liu YH, He N, Zhang J, Zhou PH, Li M, GuanT, Liu JR (2015)Tocotrienol-rich fraction (TRF) suppresses the growth of human colon cancer xenografts in Balb/C nude mice by the Wnt pathway. PLoS One 10, e0122175.
15. Peh HY, Tan WS, Liao W, Wong WS (2015) Vitamin E therapy beyond cancer: Tocopherol versus tocotrienol. Pharmacol Ther 162, 152-169.
16. Pearce BC, Parker RA, Deason ME, Qureshi AA, Wright JJ (1992) Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem 35, 3595-3606.
17. Pearce BC, Parker RA, Deason ME, Dischino DD, Gillespie E, Qureshi AA, Volk K, Wright JJ (1994) Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. J Med Chem 37, 526-541.
18. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 311, 33-44.
19. Frank J, Chin XWD, Schrader C, Eckert GP, Rimbach G (2012) Do tocotrienols have potential as neuroprotective dietary factors? Ageing Res Rev 11, 163-180.
20. Gillette-Guyonnet S, Secher M, Vellas B (2013) Nutrition and neurodegeneration: Epidemiological evidence and challenges for future research. Br J Clin Pharmacol 75, 738-755.
21. La Fata G, Weber P, Mohajeri MH (2014) Effects of vitamin E on cognitive performance during ageing and in Alzheimer's disease. Nutrients 6, 5453-5472.
22. Yang SG, Wang WY, Ling TJ, Feng Y, Du XT, Zhang X, Sun XX, Zhao M, Xue D, Yang Y, Liu RT (2010) Alpha-Tocopherol quinone inhibits beta-amyloid aggregation and cytotoxicity, disaggregates preformed fibrils and decreases the production of reactive oxygen species, NO and inflammatory cytokines. Neurochem Int 57, 914-922.
23. Mangialasche F, Xu W, Kivipelto M, Costanzi E, Ercolani S, Pigliautile M, Cecchetti R, Baglioni M, Simmons A, Soininen H, Tsolaki M, Kloszewska I, Vellas B, Lovestone S, Mecocci P (2012) Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol Aging 33, 2282-2290.
24. Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K, Winblad B, Fratiglioni L (2010) High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. J Alzheimers Dis 20, 1029-1037.
25. Khanna S, Roy S, Parinandi NL, Maurer M, Sen CK (2006) Characterization of the potent neuroprotective properties of the natural vitamin E alpha-tocotrienol. J Neurochem 98, 1474-1486.
26. Mazlan M, Johari RR, Hamid NAA (2009) Induction of DNA damage and cell death by beta amyloid peptide and its modification by tocotrienol rich fraction (TRF). Med Health 4, 8-15.
27. Selvaraju TR, Khaza'ai H, Vidyadaran S, Abd Mutalib MS, Vasudevan R (2014) The neuroprotective effects of tocotrienol rich fraction and alpha tocopherol against glutamate injury in astrocytes. Bosn J Basic Med Sci 14, 195-204.
28. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ, Pratico D (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 18, 323-325.
29. Nesaretnam K, Khor HT, Ganeson J, Chong YH, Sundram K, GaporA(1992) The effect of vitamin E tocotrienols from palm oil on chemically induced mammary carcinogenesis in female rats. Nutr Res 12, 879-892.
30. Khee SG, Yusof YA, Makpol S (2014) Expression of senescence-associated microRNAs and target genes in cellular aging and modulation by tocotrienol-rich fraction. Oxid Med Cell Longev 2014, 725929.
31. Yanagisawa D, Ibrahim NF, Taguchi H, Morikawa S, Hirao K, Shirai N, Sogabe T, Tooyama I (2015) Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. Neurobiol Aging 36, 201-210.
32. Ono K, Condron MM, Teplow DB (2009) Structureneurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A 106, 14745-14750.
33. Zhang R, Xue G, Wang S, Zhang L, Shi C, Xie X (2012) Novel object recognition as a facile behavior test for evaluating drug effects in AbetaPP/PS1 Alzheimer's disease mouse model. J Alzheimers Dis 31, 801-812.
34. Ly PT, Cai F, Song W (2011) Detection of neuritic plaques in Alzheimer's disease mouse model. J Vis Exp 15, 108.
35. Snellman A, Lopez-Picon FR, Rokka J, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M (2013) Longitudinal amyloid imaging in mouse brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med 54, 1434-1441.
36. Humpel C (2015) Organotypic vibrosections from whole brain adult Alzheimer mice (overexpressing amyloidprecursor-protein with the Swedish-Dutch-Iowa mutations) as a model to study clearance of beta-amyloid plaques. Front Aging Neurosci 7, 47.
37. Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, Buttini M (2004) Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 165, 987-995.
38. Serpell LC (2000) Alzheimer's amyloid fibrils: Structure and assembly. Biochim Biophys Acta 1502, 16-30.
39. Masters CL, Selkoe DJ (2012) Biochemistry of amyloid -protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006262.
40. Porat Y, Abramowitz A, Gazit E (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67, 27-37.
41. Azriel R, Gazit E (2001) Analysis of the minimal amyloidforming fragment of the islet amyloid polypeptide. An experimental support for the key role of the phenylalanine residue in amyloid formation. J Biol Chem 276, 34156-34161.
42. Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LC (2005) Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci U S A 102, 315-320.
43. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M (2003) Potent anti-amyloidogenic and fibrildestabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87, 172-181.
44. Ono K, Hasegawa K, Naiki H, Yamada M (2004) Antiamyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochim Biophys Acta 1690, 193-202.
45. Herrup K (2015) The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 18, 794-799.
46. Jagust W (2016) Is amyloid-beta harmful to the brain? Insights from human imaging studies. Brain 139, 23-30.
47. Moscardo E, Salvetti B, Becchi S, Bertini G, Fabene PF (2012) The novel object recognition test in rodents: Which are the essential methodological aspects? Measuring Behavior 2012, 476.
48. Jin JL, Liou AK, Shi Y, Yin KL, Chen L, Li LL, Zhu XL, Qian L, Yang R, Chen J, Xu Y (2015) CART treatment improves memory and synaptic structure in APP/PS1 mice. Sci Rep 5, 10224.
49. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, HenekaMT(2010) Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 57, 375-382.
50. Guo HB, Cheng YF, Wu JG, Wang CM, Wang HT, Zhang C, Qiu ZK, Xu JP (2015) Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation. Neuroscience 290, 530-542.
51. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24, 516-524.
52. Podda M, Weber C, Traber MG, Packer L (1996) Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinols, and ubiquinones. J Lipid Res 37, 893-901.
53. Roy S, Lado BH, Khanna S, Sen CK (2002) Vitamin E sensitive genes in the developing rat fetal brain: A highdensity oligonucleotide microarray analysis. FEBS Lett 530, 17-23.
54. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352, 2379-2388.
55. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336, 1216-1222.
56. Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, Packer L (1993) Structural and dynamic membrane properties of alpha-tocopherol and alpha-tocotrienol: Implication to the molecular mechanism of their antioxidant potency. Biochemistry 32, 10692-10699.
57. Sen CK, Khanna S, Roy S, Packer L (2000) Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamateinduced pp60(c-Src) kinase activation and death of HT4 neuronal cells. J Biol Chem 275, 13049-13055.